2-(4-fluorophenyl)-5-piperazin-1-yl-1H-imidazo[4,5-b]pyridine | 337902-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-fluorophenyl)-5-piperazin-1-yl-1H-imidazo[4,5-b]pyridine
• CAS: 337902-87-1
• 化学式: C₁₆H₁₆FN₅
• 分子量: 297.335
• InChiKey: IHMKFBWKMPEVCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  56.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-fluorophenyl)-5-piperazin-1-yl-1H-imidazo[4,5-b]pyridine 在 盐酸 、 sodium carbonate 、 溶剂黄146 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 N-cyclopentyl-4-[2-(4-fluorophenyl)-5-piperazin-1-ylimidazo[4,5-b]pyridin-1-yl]pyrimidin-2-amine
  参考文献：
  名称：

  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

  摘要：

  A library of trisubstituted oxazoles, thiazoles, imidazoles (1,2,4- and 2,4,5-substituted) and imidazo[1,2-b]pyridines was prepared and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Four structures 32, 37, 45 and 59-were identified as potent inhibitors of p38alpha with high efficacy in the LPS induced TNFalpha release model in the mouse, the adjuvant induced arthritis and the collagen induced arthritis in the rat with ED(50)s between 1.0 and 9.5 mg/kg p.o. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.106
• 作为产物：
  描述：

  2-氨基-3-硝基-6-氯吡啶 在 palladium on activated charcoal PPA 、 氢气 作用下， 以 乙醇 、 异丙醇 为溶剂， 生成 2-(4-fluorophenyl)-5-piperazin-1-yl-1H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

  摘要：

  A library of trisubstituted oxazoles, thiazoles, imidazoles (1,2,4- and 2,4,5-substituted) and imidazo[1,2-b]pyridines was prepared and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Four structures 32, 37, 45 and 59-were identified as potent inhibitors of p38alpha with high efficacy in the LPS induced TNFalpha release model in the mouse, the adjuvant induced arthritis and the collagen induced arthritis in the rat with ED(50)s between 1.0 and 9.5 mg/kg p.o. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.106

文献信息

• Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use
  申请人：——

  公开号：US20040082604A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) 1 and pharmaceutically-acceptable and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNF&agr; and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

  公式（I）1的化合物及其药学上可接受和可分解酯和酸盐加合物是MAP激酶抑制剂，对于治疗由TNF&agr;和IL-1介导的疾病如类风湿性关节炎和骨代谢疾病，例如骨质疏松症，在药学上是有用的。其中符号的定义如上所述。
• THIAZOLE AND IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  申请人：Novartis AG

  公开号：EP1224185A1

  公开（公告）日：2002-07-24
• US6608072B1
  申请人：——

  公开号：US6608072B1

  公开（公告）日：2003-08-19
• US6891039B2
  申请人：——

  公开号：US6891039B2

  公开（公告）日：2005-05-10
• [EN] THIAZOLE AND IMIDAZO [4,5-B] PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE<br/>[FR] COMPOSES THIAZOLE ET IMIDAZO [4,5-B] PYRIDINE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：NOVARTIS AG

  公开号：WO2001030778A1

  公开（公告）日：2001-05-03

  Compounds of formula (I) and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.